Blue Jet Healthcare Limited Earnings Summary — Q4 FY2026

• Revenue showed a strong sequential recovery of 21.96% compared to Q3 FY26, although it remained down year-on-year.
• Net profit for the quarter reached ₹643.44 million, recovering significantly from the ₹401.66 million reported in the prior quarter.
• The Board recommended a final dividend of ₹1.20 per equity share (60% of face value) for the financial year ended March 31, 2026.
• Company approved a massive fund-raising proposal of up to ₹10,000 million (₹1,000 Cr) via QIP, preferential issue, or other equity-linked instruments.
• Capital Work in Progress (CWIP) surged to ₹3,013.76 million compared to ₹888.84 million in the previous year, signaling heavy ongoing capacity expansion.
• Blue Jet maintains a debt-free profile with significant cash and cash equivalents and current investments totaling nearly ₹2,875 million.
• Inventories significantly decreased from ₹2,639 million to ₹1,873 million year-on-year, indicating better working capital management.
• The company operates as a single reportable business segment focused on pharma intermediates, contrast media, and sweeteners.

The company is transitioning through a significant expansion phase, as evidenced by the surge in Capital Work in Progress and the proposal to raise ₹10,000 million in new capital. This capital is intended for organic or inorganic growth to leverage its dominant global market share in niche segments.

Improving

While year-on-year comparisons are down across both revenue and profit, the sharp sequential recovery in Q4 and the massive capital raise plans suggest a pivot toward a new growth cycle.

The outlook is defined by substantial upcoming capacity as CWIP is commissioned. The ₹1,000 Cr fundraise suggests management is preparing for large-scale strategic moves or forward integration, likely targeting the Contrast Media and High-Intensity Sweetener markets.